Integer initiated with a Buy at Truist

Truist initiated coverage of Integer with a Buy rating and $137 price target. Truist says Integer is one of the largest medical device outsource manufacturers and a unique SMID given high-teens EPS growth prospects, rising exposure to emerging product cycles across MedTech through the supply chain, a durable tuck-in strategy that should add 1%-2% on top of a high single digit organization top-line, the analyst tells investors in a research note.